✦ LIBER ✦

A Dose-Escalation Study of SAR3419, an Anti-CD19 Antibody Maytansinoid Conjugate, Administered by Intravenous Infusion Once Weekly in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

✍ Scribed by Ribrag, V.; Dupuis, J.; Tilly, H.; Morschhauser, F.; Laine, F.; Houot, R.; Haioun, C.; Copie, C.; Varga, A.; Lambert, J.; Hatteville, L.; Ziti-Ljajic, S.; Caron, A.; Payrard, S.; Coiffier, B.

Book ID: 124152305
Publisher: American Association for Cancer Research
Year: 2013
Tongue: English
Weight: 295 KB
Volume: 20
Category: Article
ISSN: 1078-0432
DOI: 10.1158/1078-0432.CCR-13-0580

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I Multidose-Escalation Study of th

Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma

✍ Younes, A.; Kim, S.; Romaguera, J.; Copeland, A.; Farial, S. d. C.; Kwak, L. W.; 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 268 KB

Immunotherapy with FBTA05 (Bi20), a trif

Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial

✍ Raymund Buhmann, Stanglmaier Michael, Hess Juergen… 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 328 KB